Cargando…
Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition
Everolimus, an orally administered mammalian target of rapamycin inhibitor, has been widely used as an immunosuppressant and an anticancer agent. Whereas everolimus can control recurrent hypoglycemia in patients with insulinoma, possibly through tumor regression and/or the direct inhibition of insul...
Autores principales: | Suzuki, Luka, Miyatsuka, Takeshi, Himuro, Miwa, Nishio, Rie, Goto, Hiromasa, Uchida, Toyoyoshi, Nishida, Yuya, Kanazawa, Akio, Watada, Hirotaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007247/ https://www.ncbi.nlm.nih.gov/pubmed/29942923 http://dx.doi.org/10.1210/js.2017-00475 |
Ejemplares similares
-
Efficacy and Safety of Vildagliptin as an Add-On Therapy in Inadequately Controlled Type 2 Diabetes Patients Treated With Basal Insulin
por: Saito, Daisuke, et al.
Publicado: (2017) -
Suppression of STAT3 signaling promotes cellular reprogramming into insulin-producing cells induced by defined transcription factors
por: Miura, Masaki, et al.
Publicado: (2018) -
Cellular Autophagy in α Cells Plays a Role in the Maintenance of Islet Architecture
por: Himuro, Miwa, et al.
Publicado: (2019) -
STAT3 suppression and β-cell ablation enhance α-to-β reprogramming mediated by Pdx1
por: Wakabayashi, Yuka, et al.
Publicado: (2022) -
Switching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study
por: Tosaka, Yuka, et al.
Publicado: (2015)